Understanding clinical trials in migraine by P. Tfelt-Hansen
Introduction
Controlled randomised clinical trials (RCTs) are the basis
for evidence-based medicine in migraine. Every clinician
should therefore know how to understand and judge a
clinical trial. A clinical trial is a long process that ends in
the final study report and the publication of a paper in a
peer-reviewed journal. There are many steps in this com-
plicated process, and in order to understand the final prod-
uct, the published article, some knowledge of the previous
steps is desirable and useful.
This article will therefore try to help clinicians to
understand how a clinical trial in migraine is or should be
performed. Next, the article should be analysed critically
and some points that can be used in such an analysis will
be given. Finally, meta-analyses in migraine will be
reviewed. For more general aspects on these points the
reader is referred to References [1–9].
How a clinical trial in migraine is done
The most important steps in a RCT in migraine are sum-
marised in Table 1. The general concept of a RCT in
migraine is normally conceived by the pharmaceutical
industry. As mentioned later in detail, the aim can be
either to demonstrate that a drug is efficacious, that it is
better than placebo, or better than a standard drug for
some features, either efficacy or adverse events (AEs).
The protocol is then written and depending on the aim of
the RCT the number of subjects needed is calculated in the
power calculations. Then suitable investigators are
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sought. In phase II RCTs and early phase III it will most
often be headache specialists from headache clinics
whereas in later phase III RCTs general neurologists and
in some cases general practitioners may be recruited. The
protocol is then approved by health authorities and ethical
committees. In some cases ethical committees may object
to the inclusion of placebo in comparative RCTs [10] but
placebo is needed in order to test the reactivity of the sam-
ple [11]. Subjects are then recruited with inclusion and
exclusion criteria either from the files of the investigator,
from GPs or by general advertisement in newspapers. It is
a general experience that the number of patients that fulfil
the inclusion and exclusion criteria in one’s files is less
than expected (“the law of disappearing disease”). The
trial is then performed. In acute RCTs there is most often
one inclusion visit and one visit after the patients have
treated an attack and filled in an attack report form. In
some RCTs one tries to get the control visit within 7 days
so that missing data can be filled in [12, 13]. During the
prophylactic RCTs the patients keep a headache diary both
during the run-in phase and during the treatment period.
Control visits where headache dairies are collected are
scheduled most often with an interval of 4 weeks.
Throughout the RCTs the study is monitored by monitors
collecting the case records and in some cases, especially
in phase II RCTs, biochemical tests are done for safety
reasons. The trial data are thus continuously collected and
entered into a database, which is analysed as soon as the
database is cleared. A detailed study report with demo-
graphics, results of the RCTs and safety data is then writ-
ten up and then normally presented to a senior investiga-
tor who approves the report. A group of investigators
(most often well recognised investigators), and in some
cases also company employees, then form the publication
committee for the RCT. Ideally the publication committee
should be selected by all investigators before the start of
the RCT, but this is very rarely done. One of the tasks of
the publication committee is to decide on which journal to
submit the final manuscript to (for impact of the journal,
see later). In many cases the first draft of a manuscript is
written by a professional medical writer based on the final
study report. The authors who should have access to the
final study report then comment on the manuscript, and
their comments are then included. After some rounds of
comments the final manuscript is submitted to the chosen
journal. The decision of the editor is in many cases to pub-
lish on condition that some revision is done. This revision
is then done by the publication committee, the paper re-
submitted, and after some time, most often several
months, the article is finally published.
It is estimated that the total time from the perception of
an idea for a RCT to final publication is 3–5 years. The
whole process is complicated and is in most cases funded
and controlled by the pharmaceutical industry. There are,
however, exceptions to this general rule, for example a
RCT on riboflavin for migraine prophylaxis [14], which
was conceived and funded independently.
Understanding a paper on drug trials in migraine
Aim and results of study
The aim of the first RCTs of a new drug, for example
sumatriptan and topiramate, is to demonstrate that it is
superior to placebo and define the dose-response curve
[15–17]. All triptans were superior to placebo [18, 19];
and in most cases a dose-response curve was defined [20].
Furthermore, RCTs are performed comparing standard
treatment with the new drug, for example ergotamine with
sumatriptan [21] and propranolol with topiramate [22]. In a
comparative RCT one can get a good impression of the aim
of study by looking at the power calculations. This will
show whether a difference or comparability is expected.
When a new triptan is compared to the standard triptan
sumatriptan, the aim can be to demonstrate that:
- the new triptan is more effective for headache relief
than the standard drug;
- the new triptan is equivalent to the standard drug with
less AEs;
- the new triptan results in less AEs than the standard
drug;
- the new triptan is better for freedom from pain after
2 h;
- the new triptan is better for sustained freedom from
pain results;
Table 1. Most important steps in a clinical trial in migraine
Conception of the basic idea of the trial 
(most often by the pharmaceutical industry)
Protocol written and investigators recruited
Protocol approved by health authorities and ethical committees
Subjects recruited
Trial actually performed, and monitoring of trial
Trial data collected and trial analysed
Final report approved by senior investigator
Selection of authors (well recognised investigators)
First draft of paper written
Authors comments included
Final paper submitted to a journal
Referees’ comments included
Publication of the paper
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- the new triptan has a quicker onset of action than the
standard drug.
If one looks at the different triptan trial programmes,
one can deduct the following about the aim of these pro-
grammes: AstraZeneca (zolmitriptan) went for a better
complete response (a decrease of headache to none or
mild and no recurrence). The complete response was,
however, not different between zolmitriptan and sumatrip-
tan and not different from placebo [23], most likely due to
a high placebo response [11]. GlaxoWelcome (naratriptan)
went for less AEs and less recurrences. The chosen 2.5 mg
dose of naratriptan was chosen as a dose causing no more
AEs than placebo [20]. This dose of naratriptan was infe-
rior to sumatriptan, but higher doses of naratriptan were
equivalent to sumatriptan [20]. In one RCT with recur-
rence-prone patients there were less recurrences after
naratriptan than after sumatriptan [24]. Merck (rizatrip-
tan) went for a quicker onset of action. In two RCTs riza-
triptan had a quicker onset of action than sumatriptan [13,
14], whereas this was not the case in one RCT published
much later [25]. Almirall (almotriptan) probably went for
superior efficacy and for less AEs. In one comparative
RCT [26] and in a meta-analysis [18, 19] 12.5 mg
almotriptan caused no more AEs than placebo and less
AEs than 100 mg sumatriptan. In the comparative RCT
[26] and in the meta-analysis [18, 19] 12.5 mg almotrip-
tan was comparable to 100 mg sumatriptan and apparent-
ly better for sustained freedom from pain in the meta-
analysis [18, 19]; but in one large comparative RCT [27]
50 mg sumatriptan (25%) was superior to 12.5 mg
almotriptan (18%) for freedom from pain after 2 h and
also better for sustained freedom from pain [28]. Pfizer
(eletriptan) went for more efficacy, and in one systematic
review of 3 comparative RCTs 40 mg sumatriptan was
superior to 100 mg sumatriptan [29]. Quintiles (frovatrip-
tan), because of the 26-h half-life of frovatriptan [20],
probably went for less recurrences and less AEs. In one
comparative RTC the AEs were less after 2.5 mg frova-
triptan than with 100 mg sumatriptan [30] (but the effica-
cy data including the recurrence rates from this RCT
remain so far unpublished).
Johnson & Johnson (topiramate) went for comparabili-
ty with propranolol and in one rather large RCT 100 mg
topiramate was comparable with 160 mg propranolol [22].
Design of the study
A placebo control is needed in most cases. The subjective
nature of the response measured in migraine trials, and the
variable and sometimes high placebo response, up to 40%
in acute treatment RCTs [13] and up to 47% in prophylac-
tic RCTs [31], necessitate the use of the double-blind tech-
nique. To use a standard drug for comparison without
placebo is similar to using historical controls, a method
not to be recommended for controlled drug trials. If the
stated aim of the study is to demonstrate that a new drug
is better than a standard drug, then the standard drug will
take the place of a placebo.
Either crossover or parallel group comparisons can be
used in drug trials in migraine. Opinion is divided as to
their relative merits and the practical consequences of the
drawbacks (for example carryover effect, problems with
blinding, etc.) of the crossover trial [11]. The main advan-
tage of the crossover trial is its power, the probability of
detecting a certain difference between treatments. In addi-
tion, with decreased variability in the crossover RCT com-
pared with the group comparison, the probability of narrow
95% CI in comparative RCTs will increase. Furthermore,
this design is often more powerful in detecting significant
differences in AEs [32], and one can ask for the patient’s
preference with this design. The trend in acute treatment
trials has been to use parallel group comparison [20], but
this design demands inclusion of several hundred patients
in each treatment group if comparability is to be demon-
strated with narrow confidence limits. Approximately 500
subjects in each treatment arm were needed to demonstrate
difference in speed of onset of headache relief [13]; even
more if superiority on efficacy measures such as sustained
pain free is to be demonstrated [33].
In prophylactic RCT the crossover design was previ-
ously used a lot [34], but in recent years large RCTs,
including several hundreds of patients [16, 17, 22], have
successfully used the parallel group design. The mini-
mum effective dose (50 mg topiramate) and the optimum
dose (100 mg topiramate) have been defined in these
RCTs [16, 17, 22].
Efficacy measures
Acute treatment RCTs
Simple efficacy parameters such as the proportion of
headaches resolved within 2 h of taking the drug [11]
should be used. Only then can the clinician judge whether
a clinically relevant effect has been observed. Another
clinically relevant efficacy parameter is sustained freedom
from pain [11, 18, 19]. In most migraine RCTs with trip-
tans, headache relief, a decrease from severe or moderate
headache to none or mild headache, has been used as the
primary efficacy measure [18, 19, 35, 36]. This efficacy
measure includes a decrease from moderate to mild




Migraine attack frequency should be used as the primary
efficacy measure; indeed, most trials of active drugs have
shown that efficacy is related to this parameter. The num-
ber of days the patient has migraine over a given time is
also an acceptable efficacy measure and is simpler for the
patients to record.
Treatment-limiting AEs are especially important in pro-
phylactic trials [16, 17, 22], and in clinical practice,
because many patients stop treatment because of them. So
if the report on a prophylactic RCT indicates that active
drug and placebo give rise to similar side effect incidences,
the result should be treated with caution because it is prob-
ably attributable either to an inadequate AE reporting sys-
tem or to the trial including too few patients [9].
Presentation of results
Preferably, the results of all the objectives stated in the
study protocol should be presented in a subsequent publi-
cation [8]. The most fair and informative way of present-
ing the results is to give the confidence interval (CI), usu-
ally a 95% CI interval. When comparability of two active
drugs is claimed, this should be evidenced by a narrow
confidence interval.
The choice of journal is also important. The article can
be published in a headache journal, a neurological journal
or in a distinguished general medical journal. My impres-
sion of the impact of papers on sumatriptan is shown in
Table 2. The sumatriptan articles published in JAMA,
NEJM and The Lancet had most likely the greatest impact
(+++++). One problem with papers published in these
prestigious journals is that in some cases not all the objec-
tives can be presented. In one whole issue of European
Neurology there were only articles on sumatriptan and this
had a considerable impact (++++) because this issue was
suitable as a handout. Most of the other published papers
had, in my opinion, only moderate impact (++ to +++).
Understanding meta-analyses
Within recent years several systematic reviews with meta-
analyses of acute migraine treatment have been published
[18, 19, 36, 48–54]. In addition, three systematic reviews
of preventive migraine treatment have been published [48,
55–57]. One should distinguish between systematic
reviews, where several RCTs of a single drug are evaluat-
ed by meta-analysis to get a more precise impression of its
merits [49, 52, 53], and systematic reviews, where sever-
al drugs or administration forms of a drug are compared in
a meta-analysis [19, 36, 48, 50, 52, 54].
In the systematic reviews of acute migraine treatment
[18, 19, 36, 49–54, 58, 59], migraine was diagnosed
according to the criteria of the IHS [60] and the same
methodology was used [35]. Patients treated had moderate
or severe headache and headache relief was defined as a
decrease to none or mild [35], and this was the primary
efficacy measure in most RCTs. Freedom from pain after
2 h, which is now the recommended primary efficacy
measure of the Subcommittee of IHS on Clinical Trials
[11], was also reported in most studies and was evaluated
Table 2 Published RCTs on sumatriptan in different kinds of medical journals together with the author’s judgement of the impact on clin-
ical practice (+ ,weak to +++++, big impact)
Publication Sponsor Impact on clinical practice (+ to +++++)
NEJM 1991 [38] subc suma G +++++
JAMA 1991 [39] subc suma G +++++
Eur Neurol [15] oral suma, Subc suma [40] G ++++
Eur Neurol [41] oral suma vs. A+M G ++
J Intern Med [42] subc suma G ++
Arch Neurol [43] subc suma G ++
Cephalalgia [44] subc suma G ++
Cephalalgia [45] subc suma G ++
Neurology [46] oral suma G ++
Lancet 1995 [47] oral suma vs. A+M S +++++
From 1996 to 2003 mostly comparative V ++ to +++
RCTs with other triptans vs. oral suma [20]
G, Glaxo; S, Synthelabo; V, various sponsors (GlaxoWellcome, AstraZeneca, Merck, Almirall-Prodesfarma, Pfizer); suma, sumatriptan;
A, aspirin; M, metoclopramide; subc, subcutaneous
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in some meta-analyses [18, 19, 58, 59]. One of the meta-
analyses [18, 19] also evaluated sustained freedom from
pain, that is freedom from pain after 2 h, no use of rescue
medication and no recurrence within 24 h, and consisten-
cy across attacks.
In addition, tolerability vs. placebo was evaluated in
these systematic reviews.
The results of the meta-analysis of oral triptans [18,
19] for headache relief and freedom from pain within 2 h
are shown in Fig. 1. Because the placebo response varies
in different trial programmes the main emphasis when
judging the results of the meta-analysis should be on ther-
apeutic gains (percentage effect after active drug minus
percentage effect after placebo [48]). From therapeutic
gains it is evident that 2.5 mg frovatriptan is inferior to
and 80 mg eletriptan superior to 100 mg sumatriptan for
headache relief. For freedom from pain 10 mg rizatriptan
and 80 mg eletriptan are superior to 100 mg sumatriptan.
The results of the meta-analysis [18, 19] cannot stand
alone and the triptans should be judged by a combination
of results from the meta-analysis  and the comparative
RCTs with the triptans [48]. Such a combined evaluation
of oral triptans is presented in Table 3. For details, see
Ref. [48]. Results are generally the same in the meta-
Table 3 My personal comparison of the main efficacy and tolerability measures for selected oral triptans vs. 100 mg sumatriptan based
on the results of the meta-analysis [18], direct comparative trials [19] and later published results [27, 33, 48], modified from [19]
Initial 2 h relief Sustained freedom from pain Consistency Tolerability
Sumatriptan 50 mg = = ? =
Zolmitriptan 2.5 mg = = ? =
Zolmitriptan 5 mg = = ? =
Naratriptan – – – ++
Rizatriptan 10 mg =/+ +/= ++a =
Eletriptan 40 mg + +/= = =
Eletriptan 80 mg + + = –
Almotriptan 12.5 mg = = = ++
=, no difference when compared with 100 mg sumatriptan; +, better when compared with sumatriptan; –, inferior when compared with
sumatriptan
aConsistency for rizatriptan 10 mg was investigated with a different methodology than normally used in the meta-analysis
Fig. 1 Headache response
(relief) (a) and relief from
pain within 2 h (b) after
seven triptans. The shaded
area indicates the 95%
confidence intervals for
sumatriptan 100 mg both
for absolute responses and
placebo-subtracted results
(from [18], with permis-
sion from the publisher)
a b
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analysis and in the comparative trials, with some excep-
tions: in the comparative RCTs 40 mg eletriptan is superi-
or to 100 mg sumatriptan for headache relief and freedom
from pain [29]; and 12.5 mg almotriptan is inferior to 50
mg sumatriptan for freedom from pain and sustained free-
dom from pain [27, 28].
When comparing drugs for the acute treatment of
migraine, head-to-head comparative RCTs should remain
the “gold standard”. Comparative trials are, however, with
a few exceptions [12, 33, 48], relatively small and may
overlook differences. In theory, there may be a selection
bias in head-to-head RCTs: patient responding well to the
standard drug may be less likely to participate. In addi-
tion, not all drugs in a class of drugs will be compared in
head-to-head RTCs [48].
Meta-analyses of drugs that underwent placebo-con-
trolled RCTs with similar methodology can therefore be a
useful supplement when drugs are compared. The main
weakness of the meta-analytic approach is that there is no
randomisation. In addition, the populations may not be total-
ly comparable: there is possible bias in time with recruiting
over many years, instructions to patients may vary and
severity of headache (moderate/severe) may differ in differ-
ent trial programmes. The problem with different severity of
treated headaches is to some extent overcome by the use of
therapeutic gain, as the placebo response also varies with the
severity [61]. The main emphasis when judging meta-ana-
lytic results should therefore be on therapeutic gains and
these results should be evaluated in context with the findings
from head-to-head comparative trials.
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